Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials — Elise F. Nassif (2022) | RDL Network
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
Early phase trials provide an active therapeutic option for STS, even in first-line settings. Molecular screening and histology-driven trials further improve the clinical benefit.
Marianne Zoghbi, Bharti Patel, Matthieu Roulleaux Dugage, Laura Mezquita, Rastilav Bahleda, Armelle Dufresne, Mehdi Brahmi, Isabelle Ray‐Coquard, Patricia Pautier, Jean Yves Blay, Axel Le Cesne, Christophe Massard, Benjamin Besse, Édouard Auclin, Elise F. Nassif
Antoîne Italiano, Alban Bessede, Emmanuelle Bompas, Sophie Piperno‐Neumann, Christine Chevreau, Nicolas Penel, François Bertucci, Maud Toulmonde, Carine Bellera, Jean‐Philippe Guégan, Catherine Sautès‐Fridman, Antoine Bougoüin, Coralie Cantarel, François Le Loarer, Jean Yves Blay, Wolf H. Fridman
François Bertucci, Pascal Finetti, Lénaïg Mescam, Audrey Monneur, A Frejafon, Axel Le Cesne, Isabelle Treilleux, Antoîne Italiano, M. Brahmi, Jean Yves Blay, Émilie Mamessier
Discussion(0)
No comments yet. Be the first to comment.